H igh perfusion flow and increased vascular responsiveness (VR) are involved in the development of arterial hypertension. 1, 2 Under high perfusion flow, vasodilation takes place. [3] [4] [5] Many studies have shown that this vasodilation is largely dependent on nitric oxide (NO) released by endothelial cells. [3] [4] [5] [6] [7] [8] In addition to NO, however, high flow causes the release of the vasoconstrictor endothelin-1 (ET-1) from cultured endothelial cells. 9 -11 Previously, we observed that flow-dependent vasodilation occurs also in isolated mesenteric arteries and that the stepwise increase of flow was accompanied by an increased release of cGMP and ET-1. In fact, mesenteric vascular resistances (MVR) were significantly lower under high flow, and mesenteric arteries concurrently showed increased VR to norepinephrine (NE) and potassium chloride (KCl) .
In the present study we evaluate whether the flowdependent increased VR is attributable to vasoactive substances produced by endothelium or to ET-1 released from vascular smooth muscle cells (VSMC). The experiments were performed in the isolated and in vitro-perfused arterial mesenteric bed, as it is largely involved in the in vivo regulation of peripheral resistances.
METHODS
Experiments were carried out in Sprague-Dawley rats (250 to 350 g), maintained on regular food intake and with free access to drinking water. On the day of the experiment, rats were anesthetized with intraperitoneal pentobarbital (50 mg/kg). After abdominal laparotomy, the aorta was ligated proximally to the superior mesenteric artery. A catheter (outer diameter 0.75 mm) was inserted into the mesenteric artery and tied in place. Then, the whole mesenteric bed was isolated by carefully cutting its most distal branches from the intestinal border. The isolated mesenteric bed was transferred on a warmed chamber (37°C). A T-shaped connector was attached to the catheter previously inserted into the mesenteric preparation. A line conveying physiologic salt solution (PSS) was plugged in one of two extremities of connector to perfuse the mesenteric bed. PSS was gassed with a mixture of 95% O 2 and 5% CO 2 and warmed (37°C). PSS composition was (in mmol/L): NaCl 120, KCl 4.7, CaCl 2 2.5, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 25.0, EDTA 0.026, and glucose 5.5. The scheduled flow rates perfusing mesenteric preparation were: 3.5 (this is the usual value of in vivo flow rate in rat mesenteric bed), 4.5, 5.5, 6.5 mL/min; the changes of flow rate were obtained by increasing the rotation of a peristaltic pump (Gilson Minipuls, Glasgow, United Kingdom). Each period of perfusion lasted 20 min. Pressure was measured through a transducer connected to the other extremity of the T-shaped connector; the pressure was simultaneously recorded on paper. The MVR were obtained by dividing the effective perfusion pressure by the corresponding flow rate value.
For each experimental set isolated mesenteric preparations were divided into two groups according to perfusion flow rate: constant flow rate (3.5 mL/min; CPF) and increased flow rate (4.5, 5.5, 6.5 mL/min; IPF).
In the first set of experiments MVR, VR, ET-1, and cGMP were measured in two groups of rats (15 rats each) to confirm the previous observation. 12 Subsequently other sets of experiments were carried out as follows. To ascertain the role of ET-1 produced from endothelial cells, some mesenteric arteries (CPF n ϭ 6; IPF n ϭ 6) were perfused with phosphoramidon (10 mol/L), which inhibits endothelin converting enzyme. To verify the role of other endothelium-derived vasoactive substances, in some mesenteric arteries (CPF n ϭ 11; IPF n ϭ 11) endothelium was removed with 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane-sulfonate (CHAPS). The mesenteric preparations were perfused with a solution containing the detergent (0.3%) for 2 min; then the perfusion continued with PSS for 30 min. This procedure immediately causes the complete loss of endothelium; nevertheless, in each mesenteric artery the complete removal of endothelium was ascertained by the absence of acetylcholine-dependent vasodilation (Ach; 1 mol/L) of the mesenteric bed preconstricted with NE. To evaluate the role of ET-1 produced by VSMC, the peptide was measured in homogenates of disendothelized arteries (CPF n ϭ 4; IPF n ϭ 4), whereas in other mesenteric preparations, BQ-610 (1 mol/L), an ETA receptor antagonist, was singly (CPF n ϭ 6; IPF n ϭ 6) or concurrently (CPF n ϭ 6; IPF n ϭ 6) administered to BQ-788 (1 mol/L), an ETB receptor antagonist, in disendothelized arteries. To evaluate VR all mesenteric preparations were challenged with NE (5 mol/L) and KCl (80 mmol/L). These agents were chosen because NE acts through specific receptors, whereas the vasocontriction of KCl is due to direct membrane depolarization. The vasoconstrictors were randomly administered; the second was added when the artery had completely recovered its basal tone after the previous vasoconstrictor.
Analysis of variance for repeated measurements was applied for intragroup comparisons; NewmannKeuls was used as a post-hoc test. Student's t test was also performed to assess intergroup differences. The level of statistical significance was defined as a twotailed P value of .05.
RESULTS
The release of cGMP and ET-1 is shown in Figure 1 . In CPF arteries, cGMP release (top) was constant throughout the study, whereas in IPF arteries cGMP excretion progressively increased and was always higher (P Ͻ .05) than that of CPF arteries. ET-1 release (lower) remained unchanged in CPF arteries, and it slowly increased in the presence of increasing perfusion flow, with the value measured at a rate of 6.5 mL/min being different (P Ͻ .05) from baseline as well as from CPF value.
In IPF arteries MVR (measured at 6.5 mL/min flow rate) decreased (P Ͻ .05) to a value of 6.6 Ϯ 0.6 mm Hg/mL/min, whereas in CPF arteries MVR was 9.8 Ϯ 1.2 mm Hg/mL/min. VR to NE and KCl was markedly higher (P Ͻ .005) in IPF compared to CPF (Figure 2) .
No changes of ET-1 release were observed in CPF arteries pretreated with phosphoramidon. ET-1 in the perfusate of IPF arteries before phosphoramidon administration was 6.1 Ϯ 1, 8.9 Ϯ 1.5, 10.5 Ϯ 2.2, 18.4 Ϯ 1.6, whereas after phosphoramidon administration it was 4.6 Ϯ 0.6, 6.5 Ϯ 0.8, 8.3 Ϯ 0.9, 5.9 Ϯ 0.6 (at 3.5, 4.5, 5.5, 6.5 mL/min flow rate, respectively). Nevertheless, VR was still significantly increased as observed in mesenteric arteries not perfused with phosphoramidon ( Figure 3) .
After endothelium removal, in IPF arteries, MVR was unchanged (10.0 Ϯ 0.6 v 9.6 Ϯ 1.3 mm Hg/mL/ min in CPF), but VR was still significantly increased ( Figure 3 ). In addition, the pattern of ET-1 concentration in the perfusate was similar to that observed in intact IPF arteries (Figure 1 ), but the values were lower (4.2 Ϯ 0.9, 5.9 Ϯ 1.4, 6.5 Ϯ 1.0, 10.1 Ϯ 2.7 pg/min at flow rate of 3.5, 4.5, 5.5, 6.5 mL/min). The concentration of ET-1 in artery homogenate was strikingly greater in IPF than in CPF (0.32 Ϯ 0.14 and 1.92 Ϯ 0.08 pg/g of tissue; P Ͻ .005).
VR in the absence and presence of the ET-1 receptor antagonists is shown in Figure 4 . The flow-dependent enhancement of VR in IPF arteries was completely abolished by infusing BQ-610 and no further additive effect was achieved with BQ-788.
DISCUSSION
The data of this study show that a critical association exists between flow and release of vasoactive substances. In fact, high flows decrease MVR on one hand and increase VR to agonists on the other.
A flow-dependent vasodilation has been already observed in many experimental models and it has been linked to increased release of NO. [3] [4] [5] [6] [7] [8] The results of the present study show that high flow causes vasodilation of the mesenteric bed. NO is most likely the vasoactive substance involved in this phenomenon. In fact, it is well known that cGMP is the second messenger of NO and in this study the excretion of cGMP markedly increased in parallel with the perfusion flow rate. However, ANP and CNP (c-type natriuretic peptide), also brings about elevations in intracellular cGMP; but ANP is not present in endothelial cells and the role of CNP on vascular tone regulation remains unclear.
The increased VR observed in the present study is likely due to ET-1 produced by VSMC. This hypothe- sis is suggested by the following data. In intact arteries ET-1 release was abolished by phosphoramidon, but VR remained unchanged. It should be taken in account that phosphoramidon is a nonspecific metalloproteinase inhibitor and, therefore, it may influence other endothelial vasoactive system-regulating vascular tone in addition of endothelin converting enzyme. VR was, however, still increased after endothelium removal and this strongly supports a critical role for VSMC rather than for endothelium. In addition, the release of ET-1 from IPF arteries was similar both in arteries with and without endothelium. Tissue content of ET-1 was greater in IPF than in CPF arteries. Finally, with infusion of BQ-610, VR of disendothelized IPF arteries reached a level similar to that observed in CPF arteries. An additive role of the ETB receptor could be excluded as the simultaneous block of both receptors did not further attenuate VR.
Taken together the data of this study show that in mesenteric beds high flow rate on one hand causes vasodilation and increases ET-1 production in VSMC on the other. The increased release of the peptide makes mesenteric vessels more responsive to vasoconstrictors.
It is possible to speculate that the flow-dependent ET-1 may cause, over the time, irreversible alterations in VSMC leading to a stable increase in systemic blood pressure.
